JP Morgan Chase
MYGN icon

JP Morgan Chase’s Myriad Genetics MYGN Stock Holding History

JP Morgan Chase’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-101,200
Closed -$1.69M – 5171
2016
Q4 		$1.69M Buy
+101,200
New +$1.83M ﹤0.01% 3175
2015
Q1 		– Sell
-160,000
Closed -$5.45M – 4200
2014
Q4 		$5.45M Buy
+160,000
New +$5.68M ﹤0.01% 2357

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's MYGN Position: Q1 2026 in Review

JP Morgan Chase reduced its Myriad Genetics (MYGN) stake by 31% in Q1 2026, selling an estimated $605K and leaving 263,865 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4515.

JP Morgan Chase first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $24.3M in Q2 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • JP Morgan Chase held 263,865 shares of Myriad Genetics worth $1.15M as of Q1 2026.
  • JP Morgan Chase sold 116,203 Myriad Genetics shares in Q1 2026, an estimated $605K.
  • Myriad Genetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4515 holding.
  • JP Morgan Chase first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Myriad Genetics position peaked at $24.3M in Q2 2021.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.